Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma-Reference-Cited by-同舟云学术

Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma

Published:2022-11 Issue:11 Volume:40 Page:493.e1-493.e7
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Tripathi Nishita^ORCID,Jo Yeonjung,Tripathi Abhishek,Sayegh Nicolas,Li Haoran,Nussenzveig Roberto,Haaland Benjamin,Thomas Vinay M.,Gupta Sumati,Maughan Benjamin L.,Swami Umang,Pal Sumanta K.,Grivas Petros,Agarwal Neeraj,Sirohi Deepika

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference30 articles.

1. Variants and new entities of bladder cancer;Lopez-Beltran;Histopathology,2019

2. WHO classification of tumours of the urinary system and male genital organs;Moch,2016

3. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis;Kobayashi;BJU Int,2021

4. Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy;Hajiran;J Urol,2021

5. Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma;Makise;Int J Clin Exp Pathol,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study;Journal of Thoracic Disease;2024-05

2. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin;Clinical Genitourinary Cancer;2023-10

3. Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature;Translational Oncology;2023-03